Clinical Trial Update: A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity [Phase 3]

View source ↗

Summary

Phase 3 trial completed evaluating the long-term safety, tolerability, and metabolism of a solifenacin liquid suspension in children aged 5 to 18 with neurogeni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity

Drugs mentioned

• Solifenacin Liquid Suspension (Solifenacin)

Snippet

Sponsor: Astellas Pharma Europe B.V. | Conditions: Neurogenic Detrusor Overactivity | Phase 3 | Status: COMPLETED | Results posted: 2019-05-06